Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Beginning Cash Balance (2022 - 2024)

Summit Therapeutics (SMMT) has disclosed Beginning Cash Balance for 3 consecutive years, with $75.5 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Beginning Cash Balance changed N/A year-over-year to $75.5 million, compared with a TTM value of $151.0 million through Dec 2025, changed 0.0%, and an annual FY2024 reading of $100.0 million, up 305.09% over the prior year.
  • Beginning Cash Balance was $75.5 million for Q4 2024 at Summit Therapeutics, roughly flat from $75.5 million in the prior quarter.
  • Across five years, Beginning Cash Balance topped out at $75.5 million in Q3 2024 and bottomed at $24.7 million in Q1 2023.
  • Average Beginning Cash Balance over 3 years is $50.2 million, with a median of $50.2 million recorded in 2022.